Membrane-dependent assembly of Bruton's tyrosine kinase mediated by the Proline-rich region and SH3 domain. [PDF]
Fenton AD, Chung JK.
europepmc +1 more source
The Direction of Modern Therapies in Waldenström Macroglobulinaemia. [PDF]
Blackmore S, Elsawa S, Tavana O.
europepmc +1 more source
Incidence of pneumonia among bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia: a systematic review and meta-analysis of clinical trials. [PDF]
Mahadevia H, Ponvilawan B, Shrestha A.
europepmc +1 more source
Efficacy of BTK inhibitor combined with rituximab and lenalidomide in newly diagnosed diffuse large B-cell lymphoma: a single-center, retrospective study. [PDF]
Lv Y +14 more
europepmc +1 more source
BTK-Inhibition Enhances TLR-7-Mediated Interferon-Alpha Production in pDCs by Blocking the Inhibitory BDCA-2 Pathway. [PDF]
Ceglarek L +5 more
europepmc +1 more source
Atypical X-linked agammaglobulinaemia caused by a novel BTK mutation in a selective immunoglobulin M deficiency patient [PDF]
A Etzioni +43 more
core +1 more source
Expanded CD16<sup>+</sup>CD56<sup>+</sup>Granzyme B<sup>+</sup> NK like CD8<sup>+</sup> T cells an off target effect of bruton's tyrosine kinase inhibitors in Waldenström macroglobulinemia. [PDF]
Hastak P +16 more
europepmc +1 more source
SOX11 modulates BCR signaling through the PAX5/CD19 axis for therapeutic targeting in BTK-resistant mantle cell lymphoma. [PDF]
Dutta RP +11 more
europepmc +1 more source
Establishment and Validation of a UPLC-MS/MS Method for Quantitative Determination of Zanubrutinib and Posaconazole in Rat Plasma: Application in Drug-Drug Interaction Studies. [PDF]
Xia H, Shen Y, Xu X, Wu J, Lin G, Du X.
europepmc +1 more source
Bruton Tyrosine Kinase Inhibition Limits Multiple Sclerosis Disease-Driving Inflammation While Promoting Regulatory B Cells. [PDF]
Dybowski S +9 more
europepmc +1 more source

